Shares in Johnson & Johnson (NYSE:JNJ) fell this week after the company missed the consensus top-line forecasts but pulled off earnings beats for both the 4th quarter and 2016.
Pharmaceutical sales grew 6.5% for the full-year to $33.5 billion, with an operational increase of 7.4%. Domestic sales climbed nearly 10% and international sales increased 1.8%.
Get the full story at our sister site, Drug Delivery Business News.
The post Johnson & Johnson’s earnings disappoint, but pharma rev climbs appeared first on MassDevice.